Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Chan

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Annals of Neurology|December 10, 2013
Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT studyDarrell V Lewis, Shlomo Shinnar, Dale C Hesdorffer, et al.
Molecular Oncology|June 2, 2014
Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancerTarek M A Abdel-Fatah, Roslin Russell, Nada Albarakati, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 27, 2017
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis TrialJeremy St John Thomas, Elena Provenzano, Louise Hiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Breast Cancer Research and Treatment|January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesDavid Cameron, Michelle Casey, Michael Press, et al.
Journal of Hepatology|April 18, 2016
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Oscar Puig, Bruno Daniele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Annals of Neurology|December 10, 2013
Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT studyDarrell V Lewis, Shlomo Shinnar, Dale C Hesdorffer, et al.
Molecular Oncology|June 2, 2014
Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancerTarek M A Abdel-Fatah, Roslin Russell, Nada Albarakati, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 27, 2017
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis TrialJeremy St John Thomas, Elena Provenzano, Louise Hiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Breast Cancer Research and Treatment|January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesDavid Cameron, Michelle Casey, Michael Press, et al.
Journal of Hepatology|April 18, 2016
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Oscar Puig, Bruno Daniele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Pageof 17